Jiangsu Hansoh Pharmaceutical Co., Ltd. Drug Pipeline

Jiangsu Hansoh Pharmaceutical Co., Ltd. maintains a substantial clinical development portfolio, with 64 trials registered since 2008, including 43 currently active studies. The pipeline spans from Phase 1 through Phase 4, with a distribution of 32, 9, 6, and 2 active trials, respectively. These trials cover seven therapeutic areas, but are heavily concentrated in oncology, which accounts for 35 active programs, representing 81% of the total active portfolio. Within oncology, the leading indications by active trial count are non-small cell lung cancer (NSCLC) with 11 active trials, including 3 in Phase 3; advanced solid tumors with 6 active trials; chronic myelogenous leukemia (CML) with 3 active trials; general lung cancer and renal cell carcinoma, each with 2 active trials. Beyond oncology, the company is also pursuing clinical programs in metabolic diseases (5 active trials) and immunology (2 active trials), with single active trials in infectious disease and women's health. The significant weighting of the portfolio toward oncology suggests a strategic focus on this therapeutic area.